Myocardial Ischemia – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Myocardial Ischemia – Pipeline Review, H2 2019’, provides an overview of the Myocardial Ischemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocardial Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Myocardial Ischemia

– The report reviews pipeline therapeutics for Myocardial Ischemia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Myocardial Ischemia therapeutics and enlists all their major and minor projects

– The report assesses Myocardial Ischemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Myocardial Ischemia”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Myocardial Ischemia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Myocardial Ischemia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Angionetics Inc

Aronora Inc

AstraZeneca Plc

Bayer AG

Cadrock Pty Ltd

Caladrius Biosciences Inc

Cellmid Ltd

Chrysalis BioTherapeutics Inc

CohBar Inc

Everon Biosciences Inc

Guangzhou Magpie Pharmaceutical Co Ltd

Lixte Biotechnology Holdings Inc

NoNO Inc

Omniox Inc

Q BioMed Inc

Symvivo Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Myocardial Ischemia Overview

Myocardial Ischemia Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Myocardial Ischemia Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Myocardial Ischemia Companies Involved in Therapeutics Development

Angionetics Inc

Bayer AG

Cellmid Ltd

CohBar Inc

Lixte Biotechnology Holdings Inc

NoNO Inc

Omniox Inc

Pathfinder Cell Therapy Inc

Myocardial Ischemia Drug Profiles

AB-002 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alferminogene tadenovec Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-606583 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Myocardial Ischemia, Renal Failure and Type 1 Diabetes Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMK-103 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DT-010 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Humanin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-100 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMX-4.80 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMC-6 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sirolimus Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Myocardial Ischemia Reperfusion Injury Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize TRPM7 for Oncology, Ophthalmology, Cardiovascular and Central nervous System Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Myocardial Ischemia Dormant Projects

Myocardial Ischemia Discontinued Products

Myocardial Ischemia Product Development Milestones

Featured News & Press Releases

Jan 09, 2017: Angionetics Research Head Authors Scientific American Article on Therapeutic Angiogenesis as Potential New Treatment Approach for Ischemic Heart Disease

Sep 12, 2016: Angionetics' Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease

May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities

Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum

Sep 03, 2014: Taxus Cardium to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City

Aug 13, 2014: Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene Therapy for Heart Disease in Journal of Cardiovascular Pharmacology

Jun 12, 2014: Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention

Jan 27, 2014: Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings

May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy

Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease

Oct 25, 2012: Cytori Announces Japanese Approval For Clinical Studies Of Cardiovascular And Chronic Liver Disease Cell Therapy

Mar 20, 2012: Cardium Therapeutics Initiates Generx Phase III Clinical Registration Study

Jun 15, 2011: Cardium Therapeutics's Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance For Phase III Registration Clinical Study For Coronary Artery Disease

Nov 03, 2010: Cardium Awarded Grant Under QTDP Program

Dec 08, 2006: Cardium's Generx Advances To Phase III Following Meeting With FDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development for Myocardial Ischemia, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Myocardial Ischemia – Pipeline by Angionetics Inc, H2 2019

Myocardial Ischemia – Pipeline by Aronora Inc, H2 2019

Myocardial Ischemia – Pipeline by AstraZeneca Plc, H2 2019

Myocardial Ischemia – Pipeline by Bayer AG, H2 2019

Myocardial Ischemia – Pipeline by Cadrock Pty Ltd, H2 2019

Myocardial Ischemia – Pipeline by Caladrius Biosciences Inc, H2 2019

Myocardial Ischemia – Pipeline by Cellmid Ltd, H2 2019

Myocardial Ischemia – Pipeline by Chrysalis BioTherapeutics Inc, H2 2019

Myocardial Ischemia – Pipeline by CohBar Inc, H2 2019

Myocardial Ischemia – Pipeline by Everon Biosciences Inc, H2 2019

Myocardial Ischemia – Pipeline by Guangzhou Magpie Pharmaceutical Co Ltd, H2 2019

Myocardial Ischemia – Pipeline by Lixte Biotechnology Holdings Inc, H2 2019

Myocardial Ischemia – Pipeline by NoNO Inc, H2 2019

Myocardial Ischemia – Pipeline by Omniox Inc, H2 2019

Myocardial Ischemia – Pipeline by Q BioMed Inc, H2 2019

Myocardial Ischemia – Pipeline by Symvivo Inc, H2 2019

Myocardial Ischemia – Dormant Projects, H2 2019

Myocardial Ischemia – Dormant Projects, H2 2019 (Contd..1), H2 2019

Myocardial Ischemia – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Myocardial Ischemia, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports